Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing’s sarcoma cells

Sophie L. Kerschner-Morales, Marie Kühne, Jonathan Becker, James F. Beck, Jürgen SonnemannJournal of Cancer Research and Clinical Oncology 2020 · DOI

TL;DR

This study investigates the potential of two Polo-like kinase 4 (PLK4) inhibitors, CFI-400945 and centrinone, as novel treatments for Ewing's sarcoma (ES), a rare and aggressive childhood cancer. The findings demonstrate that these inhibitors effectively induce cell death and cell cycle arrest in ES cells, suggesting they are promising candidates for further clinical investigation.

What Problem Does This Paper Address?

Ewing's sarcoma (ES) is a highly aggressive bone cancer that primarily affects children and adolescents. Despite current standard treatments involving chemotherapy, surgery, and radiation, the survival rates for patients with metastatic ES remain poor, and progress in improving treatment outcomes has plateaued. This highlights an urgent need for new therapeutic strategies and the identification of novel drug targets. Polo-like kinases (PLKs) are a family of enzymes crucial for cell cycle control, and their dysregulation is implicated in various cancers. While PLK1 has been a focus for cancer therapy, PLK4, essential for centriole biogenesis and cytokinesis, is emerging as a promising target. However, the effectiveness of PLK4 inhibitors against ES cells had not yet been established. This paper aims to fill that gap by evaluating the anticancer effects of two PLK4 inhibitors, CFI-400945 and centrinone, in different ES cell lines.

Methods

The researchers employed a multi-pronged approach to assess the effects of CFI-400945 and centrinone on ES cells:

  • Cell Culture: Three ES cell lines with varying TP53 statuses (wild-type, mutant, and null) were used to investigate the potential influence of p53 on drug response.
  • Cell Death Assessment: Flow cytometry was used to measure cell death via propidium iodide (PI) uptake, which indicates compromised cell membrane integrity.
  • Cell Viability Assay: A resazurin-based assay was performed to quantify the overall metabolic activity and viability of treated cells.
  • Mitochondrial Transmembrane Potential (ΔΨm) Decay: Flow cytometry with DiOC6(3) staining was used to detect early signs of apoptosis, characterized by the dissipation of mitochondrial membrane potential.
  • Cell Cycle Analysis: Flow cytometry with PI staining was employed to determine the distribution of cells in different phases of the cell cycle (G1, S, G2/M) and to identify cell cycle arrests or the accumulation of polyploid cells.
  • Caspase 3/7 Activity: A fluorogenic substrate assay was used to measure the activity of caspases 3 and 7, key executioners of apoptosis.
  • Immunoblotting: Western blotting was used to detect the cleavage of PARP1 (a hallmark of apoptosis) and the phosphorylation of histone H2AX (γH2AX), a marker of DNA damage.
  • Immunofluorescence Microscopy: This technique was used to visualize cellular structures, specifically a-tubulin, to observe potential effects on spindle formation and the presence of multinucleated cells.
  • Real-time RT-PCR: This method was used to quantify the expression levels of PLK4 in the ES cell lines.

To further dissect the mechanisms, experiments were conducted with and without the pan-caspase inhibitor z-VAD-fmk to determine the role of caspases in drug-induced cell death.

Datasets

Not discussed in the paper. The study utilized established Ewing's sarcoma cell lines (WE-68, SK-ES-1, and A673) and HeLa cells for comparative analysis.

Key Insights and Ideas

  • PLK4 Inhibition is Effective in ES Cells: The study provides strong evidence that targeting PLK4 with CFI-400945 and centrinone is a viable strategy for treating Ewing's sarcoma.
  • Apoptosis is a Key Mechanism: The observed mitochondrial membrane depolarization, caspase activation, PARP1 cleavage, and DNA fragmentation strongly indicate that these PLK4 inhibitors induce cell death through the apoptotic pathway.
  • Cell Cycle Arrest and Polyploidy: The inhibitors induce a G2/M cell cycle arrest, and CFI-400945, in particular, leads to the formation of polyploid cells. These effects are more pronounced when apoptosis is inhibited, suggesting that cell cycle disruption is a significant consequence of PLK4 inhibition.
  • p53 Independence: Crucially, the anticancer effects of CFI-400945 and centrinone were observed across ES cell lines with different TP53 statuses, suggesting that their efficacy is independent of functional p53. This is significant because TP53 mutations, while rare in ES, are associated with a poorer prognosis.
  • DNA Damage Induction: The PLK4 inhibitors were found to induce DNA damage, as evidenced by H2AX phosphorylation. This suggests that while targeting PLK4, these agents also contribute to cellular stress through DNA damage pathways.

Key Results

  • Cell Death: Both CFI-400945 and centrinone induced cell death in a concentration-dependent manner across all three ES cell lines. CFI-400945 was effective at nanomolar concentrations, while centrinone required micromolar concentrations.
  • Apoptosis Markers: The inhibitors consistently activated caspase 3/7 and led to PARP1 cleavage, confirming apoptosis.
  • Cell Cycle Arrest: Centrinone treatment resulted in a G2/M cell cycle arrest, while CFI-400945 predominantly promoted polyploidy. These effects were more pronounced when caspases were inhibited.
  • DNA Damage: CFI-400945 and centrinone induced H2AX phosphorylation in WE-68 cells, indicating DNA damage.

Limitations and Future Work

  • In Vitro vs. In Vivo: The study was conducted entirely in vitro. The authors acknowledge that further studies are required to confirm these findings in vivo.
  • Specificity of Inhibitors: While CFI-400945 and centrinone are described as PLK4 inhibitors, the authors note that protein kinase inhibitors are rarely fully selective. The study did not extensively explore potential off-target effects beyond PLK4.
  • Differential Effects: While both inhibitors showed efficacy, some differences in their effects on cell cycle progression were observed, particularly at a fixed time point. The authors suggest that differences in their dissociation constants and measurement time might contribute to these variations.
  • Long-term Sequelae: The induction of DNA damage by PLK4 inhibitors raises concerns about potential long-term side effects, similar to those associated with genotoxic drugs. This warrants careful consideration in future therapeutic development.

The authors conclude that CFI-400945 and centrinone are promising candidates for the treatment of Ewing's sarcoma and warrant further investigation, particularly in preclinical in vivo models. Their p53-independent activity makes them particularly attractive for a broader patient population.

Summary updated

Abstract

Our findings show that PLK4 inhibitors were effective against Ewing's sarcoma cells in vitro and thus provide a rationale for their evaluation in vivo.
BibTeX
@article{kerschnermorales2020anticancer,
  author = {Sophie L. Kerschner-Morales and Marie Kühne and Jonathan Becker and James F. Beck and Jürgen Sonnemann},
  title = {{Anticancer effects of the PLK4 inhibitors CFI-400945 and centrinone in Ewing’s sarcoma cells}},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2020},
  doi = {10.1007/s00432-020-03346-z},
}
Figure